

A flexible approach to
**Custom-Built
Research**

**AT QPS WE BELIEVE IN DEVELOPING CLOSE AND
LONG-LASTING RELATIONSHIPS WITH OUR CLIENTS**

on the basis of trust and mutual respect. This mutual trust, combined with the agile approach we offer as a specialty CRO, helps improve the quality of your outsourced clinical work and reduces the degree of required oversight.

**TIME IS OF THE ESSENCE IN DRUG DEVELOPMENT.
CONTACT THE QPS BUSINESS DEVELOPMENT TEAM TODAY!**

CALL +1 512 350 2827 **EMAIL** infobd@qps.com



JOIN THE MANY PHARMACEUTICAL AND BIOTECH COMPANIES THAT COUNT ON QPS' GLOBAL TEAM OF QUALIFIED AND EXPERIENCED PROFESSIONALS TO DELIVER DRUG DISCOVERY AND DEVELOPMENT PROGRAMS

Neuropharmacology

QPS offers you a vast array of predictive disease models, as well as unparalleled experience with validated transgenic and non-transgenic *in vitro* and *in vivo* models covering the majority of pharmacological targets for Alzheimer's, Parkinson's, Huntington's and other neurodegenerative diseases.

Toxicology

Over the past two decades, QPS has performed thousands of GLP studies for local and international pharmaceutical and biotechnology companies, covering many different disease therapies. This vast experience attests to our ability to effectively deliver high quality toxicology data solutions at our preclinical site in Asia.

DMPK

With immediate access to a team of senior scientists with decades of pharmaceutical and biotech experience, QPS guides you through the appropriate ADME studies across a broad range of compound structures and therapeutic targets.

Bioanalysis

QPS is built on a worldwide network of resources in bioanalysis for small molecules and biologics, with state of the art facilities in the U.S., Europe and Asia. Find out how a strategic outsourcing alliance with QPS can provide you with world class operational and service excellence.

Translational Medicine

QPS offers specialized biomarker assay capabilities that support the development of targeted therapies and personalized medicines

Clinical Development

We offer industry-leading early and late phase clinical capabilities, featuring more than 500 phase I beds across the U.S., Europe and Asia. For more than 20 years, QPS' clinical research sites have collectively completed thousands of clinical trials involving tens of thousands of healthy volunteers and patients. We have studied a very wide range of molecular entities, large or small, either as part of a complex, First-in-Man, Proof of Concept (POC) program, or a larger global Phase II-IV study.

QPS is a Global CRO with locations around the world

